Astrana Health, Inc. ASTH R2K
Astrana Health, Inc., a healthcare management company, provides medical care services in the United States. The company operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company offers care coordination services to patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans. Its physician network includes primary care physicians, specialist physicians and extenders, and hospitalists. The company serves patients primarily covered by private or public insurance, such as Medicare, Medicaid, and health maintenance organization; and non-insured patients. The company was formerly known as Apollo Medical Holdings, Inc. and changed its name to Astrana Health, Inc. in February 2024. Astrana Health, Inc. was founded in 1992 and is headquartered in Alhambra, California.
READ MORE ›Market & Price
Valuation
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Growth (CAGR)
PROS
- Compounding revenue at 40.6% over 5 years.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading at a high P/E of 61.7.
- Earnings shrank at -20.7% CAGR over 5 years.
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ASTH Astrana Health, Inc. R2K | 37.62 | 61.67 | $1.87B | - | 5.58% | 5.66% | 40.62% | -20.75% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Quarterly Results
Figures in USD.
| Metric | Jun 2014 | Sep 2014 | Dec 2014 | Jun 2015 | Sep 2015 | Dec 2015 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | 122.67M | 166.73M | 95.76M | 130.05M | 156.06M | 178.75M | 165.10M | 165.17M | 180.12M | 176.78M | 176.06M | 175.64M | 227.12M | 263.26M | 269.70M | 317.00M | 337.24M | 348.21M | 348.17M | 404.36M | 486.26M | 478.71M | 620.39M | 654.81M | 956.05M | 950.53M | 965.10M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 549.06M | 576.84M | 858.86M | 855.48M | 859.36M |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 71.33M | 77.97M | 97.19M | 95.04M | 105.74M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 50.75M | 57.63M | 77.98M | 76.65M | 77.22M |
| Operating Income | -1.19M | 1.86M | -1.53M | -1.66M | -412.91K | -1.46M | -1.76M | -2.17M | -1.68M | 15.68M | 4.06M | 21.25M | 22.70M | 7.15M | 56.58M | -3.31M | 14.73M | 10.07M | 10.93M | 4.37M | 12.91M | 37.36M | 25.88M | 21.78M | 20.99M | 53.16M | 26.21M | 15.38M | 50.09M | 22.37M | 27.03M | 39.08M | 30.14M | 30.07M | 28.43M | 20.58M | 20.34M | 19.21M | 18.39M | 28.53M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 23.76M | 31.11M | 38.98M | 41.43M | 51.29M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 7.31M | 7.38M | 17.72M | 17.52M | 16.10M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 9.60M | 16.82M | 5.67M | 7.51M | 19.71M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.38M | 6.61M | 4.59M | 944.00K | 6.58M |
| Net Income | -1.68M | 1.38M | -1.69M | -2.48M | -531.37K | -1.69M | -1.32M | -1.36M | -1.73M | 4.35M | 1.99M | 5.62M | 2.16M | 2.66M | 9.11M | 140.00K | 3.54M | 3.70M | 6.73M | 4.05M | 7.04M | 16.71M | 10.06M | 13.15M | 12.66M | 34.28M | 14.26M | 11.95M | 23.18M | 13.13M | 13.17M | 22.06M | 14.84M | 19.17M | 16.09M | 6.69M | 9.42M | 373.00K | 6.00M | 14.44M |
| Diluted EPS | - | 0.26 | -0.35 | - | -0.11 | -0.31 | - | - | - | 0.15 | 0.07 | 0.20 | 0.06 | 0.07 | 0.24 | 0.00 | 0.09 | 0.10 | 0.18 | 0.11 | 0.19 | 0.45 | 0.26 | 0.30 | 0.28 | 0.74 | 0.31 | 0.26 | 0.50 | 0.28 | 0.28 | 0.47 | 0.31 | 0.40 | 0.33 | 0.14 | 0.19 | 0.01 | 0.12 | 0.29 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Jan 2011 | Jan 2012 | Jan 2013 | Jan 2014 | Mar 2015 | Mar 2016 | Dec 2016 | Mar 2017 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | 356.36M | 519.91M | 560.62M | 687.18M | - | 1.14B | 1.39B | 2.03B | 3.18B |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | 944.68M | 1.17B | 1.76B | 2.84B |
| Gross Profit | 581.86K | 978.41K | 1.46M | 1.41M | - | - | - | - | - | - | - | - | - | 199.48M | 214.96M | 271.39M | 341.53M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | 95.21M | 130.34M | 182.04M | 263.00M |
| Operating Income | 4.01K | -413.33K | -2.08M | -3.91M | -694.33K | -7.27M | 11.69M | -10.54M | 35.15M | 88.43M | 32.42M | 80.50M | - | 104.27M | 84.61M | 89.35M | 78.53M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | 112.08M | 123.69M | 141.84M | 135.28M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | 7.92M | 16.10M | 33.10M | 49.93M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | 86.62M | 89.84M | 80.82M | 39.61M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | 40.88M | 31.99M | 30.89M | 15.53M |
| Net Income | -156.33K | -720.35K | -8.90M | -5.02M | -1.80M | -9.34M | 11.45M | -8.97M | 25.80M | 10.84M | 14.12M | 37.87M | - | 45.17M | 60.72M | 43.15M | 22.49M |
| Diluted EPS | - | - | - | - | - | - | 0.41 | - | 0.90 | 0.29 | 0.39 | 1.01 | - | 1.08 | 1.29 | 0.90 | 0.46 |
Compounded Sales Growth
| 5 Years: | 40.62% |
| 1 Year: | 55.60% |
Compounded Profit Growth
| 5 Years: | -20.75% |
| 1 Year: | 110.10% |
Stock Price Performance
| 1 Year: | +51.75% |
| 6 Months: | +62.02% |
| 3 Months: | +85.05% |
| 1 Month: | +7.42% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Jan 2010 | Jan 2011 | Jan 2012 | Jan 2013 | Jan 2014 | Mar 2014 | Mar 2015 | Dec 2015 | Mar 2016 | Dec 2016 | Mar 2017 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 1.26M | 1.36M | 3.22M | 3.96M | 9.48M | 15.00M | - | 19.57M | 350.00M | 20.64M | 490.64M | 513.00M | 728.71M | 817.49M | - | 966.21M | 933.36M | 1.35B | 2.22B |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 428.12M | 461.51M | 638.50M | 863.31M |
| Cash & Equivalents | 665.74K | 397.10K | 164.36K | 1.18M | 1.45M | 6.83M | 5.01M | 59.01M | 9.27M | 54.82M | 8.66M | 99.75M | 106.89M | 103.19M | 193.47M | - | 288.03M | 293.81M | 288.45M | 429.47M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 49.63M | 76.78M | 275.99M | 374.46M |
| Total Liabilities | - | 1.34M | 1.79M | 3.61M | 5.65M | 11.11M | 15.99M | - | 11.02M | 99.56M | 20.37M | 154.32M | 106.34M | 367.65M | 372.34M | - | 407.67M | 522.59M | 840.73M | 1.66B |
| Current Liabilities | - | 92.75K | 1.52M | 1.70M | 4.55M | 2.32M | 5.97M | - | 7.43M | 50.63M | 14.54M | 109.60M | 72.02M | 105.42M | 114.99M | - | 148.61M | 218.67M | 365.61M | 615.27M |
| Long Term Debt | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 232.17M | 230.21M | - | 203.39M | 258.94M | 425.30M | 990.90M |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 229.36M | 321.01M | 470.68M | 1.08B |
| Total Equity | - | -311.31K | -659.32K | -354.88K | -2.62M | -2.41M | -2.82M | - | -1.27M | 87.21M | -353.88K | 159.95M | 180.55M | 191.55M | 330.82M | - | 542.56M | 614.22M | 712.72M | 779.29M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 56.87M | 57.43M | 58.53M | 59.46M |
Cash Flows (Annual)
Figures in USD.
| Metric | Jan 2011 | Jan 2012 | Jan 2013 | Jan 2014 | Mar 2015 | Mar 2016 | Dec 2016 | Mar 2017 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -245.03K | -385.45K | 57.96K | -1.48M | - | - | 21.91M | - | 51.83M | 25.50M | 13.67M | 46.16M | - | 82.13M | 68.23M | 52.20M | 114.60M |
| Investing Cash Flow | -21.16K | 157.00K | -31.68K | -272.93K | - | - | -8.96M | - | 26.72M | -25.18M | -180.63M | 95.49M | - | -7.11M | -65.52M | -192.40M | -539.00M |
| Financing Cash Flow | -2.44K | -4.29K | 986.10K | 2.03M | - | - | -17.15M | - | -14.98M | -11.18M | 163.33M | -51.70M | - | -20.09M | 3.42M | 135.15M | 569.35M |
| Capital Expenditure | -21.16K | -7.21K | -45.80K | -22.93K | -44.51K | -262.11K | -3.31M | -297.56K | -2.08M | -1.17M | -1.04M | -1.16M | - | -22.94M | -28.53M | -8.03M | -10.11M |
| Free Cash Flow | -266.20K | -392.66K | 12.16K | -1.50M | - | - | 18.61M | - | 49.75M | 24.33M | 12.63M | 45.00M | - | 59.19M | 39.70M | 44.17M | 104.49M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | - | - | - | 54.93M | 6.12M | -5.05M | 144.94M |
| Share Buybacks | - | - | - | 0 | 500 | - | 517.50K | - | 3.18M | 5.05M | 7.57M | 537.00K | 5.74M | 9.25M | 10.19M | 900.00K | 25.60M |
| Dividends Paid | - | - | - | - | - | - | 26.66M | - | 10.45M | 17.76M | 61.72M | - | - | - | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Jan 2011 | Jan 2012 | Jan 2013 | Jan 2014 | Mar 2015 | Mar 2016 | Dec 2016 | Mar 2017 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | 17.4% | 15.5% | 13.3% | 10.7% |
| Operating Margin % | - | - | - | - | - | - | - | - | 9.9% | 17.0% | 5.8% | 11.7% | - | 9.1% | 6.1% | 4.4% | 2.5% |
| Net Margin % | - | - | - | - | - | - | - | - | 7.2% | 2.1% | 2.5% | 5.5% | - | 3.9% | 4.4% | 2.1% | 0.7% |
| ROE % | 50.2% | 109.3% | 2,509.2% | 191.7% | 64.0% | 736.1% | 13.1% | 2,534.7% | 16.1% | 6.0% | 7.4% | 11.4% | - | 8.3% | 9.9% | 6.1% | 2.9% |
| ROCE % | 0.3% | 273.3% | -136.9% | 660.2% | -7.7% | -59.9% | 3.9% | -172.7% | 9.2% | 20.1% | 5.2% | 11.5% | - | 12.8% | 11.8% | 9.0% | 4.9% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 17.22% | 6.16M | $231.88M |
| 2 | Vanguard Portfolio Management LLC | 6.36% | 2.28M | $85.65M |
| 3 | 325 Capital Llc | 5.14% | 1.84M | $69.19M |
| 4 | Vanguard Capital Management LLC | 4.78% | 1.71M | $64.34M |
| 5 | State Street Corporation | 4.61% | 1.65M | $62.09M |
| 6 | Dimensional Fund Advisors LP | 3.82% | 1.37M | $51.47M |
| 7 | Wellington Management Group, LLP | 3.75% | 1.34M | $50.48M |
| 8 | Geode Capital Management, LLC | 2.90% | 1.04M | $39.05M |
| 9 | 683 Capital Management LLC | 1.96% | 700.00K | $26.33M |
| 10 | Charles Schwab Investment Management, Inc. | 1.80% | 644.17K | $24.23M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ASTH